<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Translocation of the c-myc protooncogene to an immunoglobulin locus is a rate-limiting step in the genesis of three B cell derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>: Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) in humans, mouse <z:hpo ids='HP_0011857'>plasmacytoma</z:hpo> (MPC), and rat <z:e sem="disease" ids="C0242647,C0334633" disease_type="Neoplastic Process" abbrv="">immunocytoma</z:e> (RIC) </plain></SENT>
<SENT sid="1" pm="."><plain>The translocation appears as a rate-limiting step in the genesis of <z:hpo ids='HP_0000001'>all</z:hpo> three <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Its consequences have been best analyzed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>They involve a non-immunological and an immunological component </plain></SENT>
<SENT sid="4" pm="."><plain>The former acts by preventing the B cell from leaving the cycling compartment and entering the resting stage when programmed to do so </plain></SENT>
<SENT sid="5" pm="."><plain>The latter acts by the down-regulation of certain human leucocyte antigen (HLA) class I polymorphic specificities, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules and Epstein-Barr virus (EBV) encoded proteins </plain></SENT>
<SENT sid="6" pm="."><plain>Together, they contribute to the escape of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell from the host immune response </plain></SENT>
<SENT sid="7" pm="."><plain>We have also described a non-clonogenic, non-tumorigenic "<z:mp ids='MP_0003171'>revertant</z:mp>", subline among five EBV-convertants of an originally highly tumorigenic, EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> line </plain></SENT>
<SENT sid="8" pm="."><plain>The other four convertants have remained highly tumorigenic </plain></SENT>
<SENT sid="9" pm="."><plain>Suppression of tumorigenicity is associated with a switch to a lymphoblastoid line (LCL)-like phenotype, accompanied by the appearance of several activation markers </plain></SENT>
<SENT sid="10" pm="."><plain>It is suggested that the LCL-type immunoblast comes under the influence of host feedback that normally contribute to the constancy of the B cell pool </plain></SENT>
</text></document>